About ERN LUNG
Expertise
patients
clinicians
ERN-LUNG Academy

The ERN-LUNG Academy is a curriculum for medical staff at any stage of their career, who wishes to get a proof of knowledge on rare respiratory diseases. It consists of Webinars and eCases, but also includes on-site training in ERN-LUNG Centers. We call for applications from participants of EU-member States from September to November each year. Classes start in January. If you wish to apply for next yearโ€™s class, please send a letter of motivation to info@ern-lung.eu

ERN-LUNG Online advance system

The EXpert Advisory BOard (EXABO) is a pan-European internet platform, which has been developed in the context of ERN-LUNG in liaison with the Medical Informatics Group of University Hospital Frankfurt, to answer questions on all aspects of rare respiratory diseases. The platform is primarily aimed at patients and care team members but is openly accessible by anyone who wants to ask a related question.

NETWORK
News

New survey aims to give under-represented countries a stronger voice in rare-disease research

A new questionnaire, โ€œPromoting capacity-development actionsโ€ โ€“ has been released under one of the teams developing the European Rare Diseases Research Alliance (ERDERA) team that focuses on harmonization of the different national capacities. The goal is simple but urgent: to capture first-hand evidence of the funding gaps, technical hurdles and policy barriers that still keep many low- and middle-income or smaller European nations on the sidelines of global rare-disease science.

The short online survey asks researchers, clinicians, patient-group leaders and policy-makers to rank the obstacles they faceโ€”whether that means scarce laboratory equipment, gaps in specialist training or a lack of national rare-disease plans. Responses will be analysed using the Delphi method: after an initial review, participants will receive a summary of the most common challenges and will be invited to confirm or refine the priorities in a second round. Everyone who completes both rounds can choose to be named in the final publication or remain anonymous.

Organisers say the evidence gathered will feed directly into the design of future ERDERA training schemes, mentoring networks and targeted funding calls aimed at countries that currently struggle to join large European projects. That matters because, while rare conditions affect an estimated 30 million people across Europe, research output and clinical trials still come mainly from a small group of well-resourced nations. Giving under-represented countries a stronger voice should help speed up diagnosis and open the door to new therapies for patients who are often left waiting the longest.

The questionnaire takes about ten minutes to complete and is available at the following link: https://forms.office.com/e/7sK6fsmqRp. The project team is encouraging universities, hospitals and patient organisations to share it widely now that the Easter break has ended. The survey will remain open until mid-May, and preliminary findings are expected to be released over the summer.